Payment overview · 2025
General Payments
$19,392.38
103 reported records · 16 companies
Healthcare provider profile · identity verified
Keshini Parbhu, MD
Allopathic & Osteopathic Physicians|Ophthalmology|Ophthalmic Plastic and Reconstructive Surgery · WINDERMERE, FL · NPI 1790832673
Verified facts
What the public records show
CMS Open Payments records show Keshini Parbhu, MD received $19,392.38 in general payments during 2025 across 103 reported records.
Amgen Inc. accounted for 78.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Miebo, Vevye, Xiidra.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Botox by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Xiidra by this doctor in 2024.
Harrow Eye, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VEVYE as an associated drug or biological on 14430 records involving 6429 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vevye by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $15,247.98 | 78.6% | 31 | 2025 |
| Lumenis BE inc | Unresolved — no canonical attribution shown | $2,000.00 | 10.3% | 1 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $488.88 | 2.5% | 9 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $451.14 | 2.3% | 17 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $334.53 | 1.7% | 8 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $234.72 | 1.2% | 4 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $213.62 | 1.1% | 12 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $139.56 | 0.7% | 10 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.23 | 0.3% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $60.69 | 0.3% | 2 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $47.78 | 0.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.84 | 0.2% | 1 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $21.91 | 0.1% | 1 | 2025 |
| Carl Zeiss Meditec USA, Inc. | Unresolved — no canonical attribution shown | $18.89 | 0.1% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.27 | 0.1% | 1 | 2025 |
| RxSight Inc | Unresolved — no canonical attribution shown | $16.34 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,862.50 | 5 |
| Food and Beverage | $4,880.83 | 94 |
| Travel and Lodging | $1,649.05 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $10,714.01 | 27 | 2025 |
Source payment records
|
|||||
| M22 Normalized: m22 |
Device | Lumenis BE inc | $2,000.00 | 1 | 2025 |
Source payment records
|
|||||
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Vision LLC | $323.06 | 5 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $268.50 | 5 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $245.22 | 4 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $231.44 | 14 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $218.53 | 3 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $213.62 | 12 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $139.56 | 10 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $66.23 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $60.69 | 2 | 2025 |
Source payment records
|
|||||
| RYZUMVI Normalized: ryzumvi |
Drug | Oyster Point Pharma, Inc. | $47.78 | 2 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $47.78 | 2 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $31.84 | 1 | 2025 |
Source payment records
|
|||||
| Rocklatan Normalized: rocklatan |
Drug | Alcon Vision LLC | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| TECNIS IOL Normalized: tecnis iol |
Device | Johnson & Johnson Surgical Vision, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| Tecnis Simplicity Normalized: tecnis simplicity |
Device | Johnson & Johnson Surgical Vision, Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| enVista Envy IOL Normalized: envista envy iol |
Device | Bausch & Lomb Americas Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| EYSUVIS Normalized: eysuvis |
Drug | Alcon Vision LLC | $20.08 | 1 | 2025 |
Source payment records
|
|||||
| CALLISTO eye Normalized: callisto eye |
Device | Carl Zeiss Meditec USA, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| Syfovre Normalized: syfovre |
Drug | Apellis Pharmaceuticals, Inc. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| LIGHT ADJUSTABLE LENS (LAL) Normalized: light adjustable lens lal |
Device | RxSight Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT CONTACT LENS Normalized: rxsight contact lens |
Device | RxSight Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR CARTRIDGE Normalized: rxsight injector cartridge |
Device | RxSight Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR HANDPIECE Normalized: rxsight injector handpiece |
Device | RxSight Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT LIGHT DELIVERY DEVICE (LDD) Normalized: rxsight light delivery device ldd |
Device | RxSight Inc | $16.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MIEBO miebo |
2025 | Miebo | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VEVYE vevye |
2025 | Vevye | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 31 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
31 | 20 |
| Harrow Eye, LLC Exact reporting entity; no affiliate inference |
2025 | VEVYE open payments reported associated product |
CMS Open Payments — General Payments 14430 supporting records · 6429 recipient NPIs · example record 1236209940 |
Vevye · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Erythromycin | Erythromycin Base | 267 | 230 |
| Tramadol Hcl | Tramadol Hcl | 175 | 169 |
| Methylprednisolone | Methylprednisolone | 99 | 97 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 85 | 73 |
| Restasis | Cyclosporine | 38 | 26 |
| Xiidra | Lifitegrast | 31 | 20 |
| Cephalexin | Cephalexin | 21 | 21 |
| Botox | Onabotulinumtoxina | 20 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 18 | 17 |
| Tobradex | Tobramycin/Dexamethasone | 15 | 13 |
| Difluprednate | Difluprednate | 13 | 12 |
| Miebo | Perfluorohexyloctane/Pf | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Vevye | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $19,392.38 · 103 records | Amgen Inc. | CALLISTO eye, Cequa, EYSUVIS, LIGHT ADJUSTABLE LENS (LAL), LUMIGAN, M22, MIEBO, OXERVATE, RXSIGHT CONTACT LENS, RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE, RXSIGHT LIGHT DELIVERY DEVICE (LDD), RYZUMVI, Rocklatan, Syfovre, TECNIS IOL, TEPEZZA, TRYPTYR, TYRVAYA, Tecnis Simplicity, VEVYE, VYZULTA, XDEMVY, XIIDRA, Xeomin, enVista Envy IOL | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Miebo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error